However, combining the angiomotin DNA vaccine with another targeting extracellular and transmembrane domains of human Her-2 resulted in dramatic tumor growth impairment in the transgenic model, demonstrating increased tumor-free survival. This evidence concerns the gene AMOT and neoplasm.